• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, April 11, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Oncotarget: Sensitivity testing on ovarian cancer cells isolated from malignant ascites

Bioengineer by Bioengineer
March 8, 2021
in Cancer
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The aim of this @Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays

IMAGE

Credit: Correspondence to – Anne M. van Altena – [email protected]

Oncotarget published “Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites” which reported that the authors aim is to determine the feasibility of cell proliferation assays of tumor cells isolated from malignant ascites to predict in vitro chemotherapy sensitivity, and to correlate these results with clinical outcome.

Cell samples were enriched for tumor cells and EOC origin was confirmed by intracellular staining of CK7, surface staining of CA125 and EpCAM, and HE4 gene expression.

In vitro sensitivity to chemotherapy was determined in cell proliferation assays using intracellular ATP content as an indirect measure of cell number.

In twelve of the fourteen remaining cases in vitro drug sensitivity and clinical outcome corresponded, while in two samples there was no correspondence.

Larger observational studies are required to confirm the correlation between the in vitro sensitivity and clinical outcome.

Dr. Anne M. van Altena from The Radboud University Medical Center said, “Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy worldwide.“

Standard first-line treatment for advanced EOC consists of a combination of a debulking surgery and chemotherapy, with paclitaxel and a platinum-based compound administered either intravenously or intraperitoneally.

There is a need for more tools and assays to predict the clinical response to chemotherapy in EOC patients.

Konecny and co-workers reported a significant decrease in progression-free and overall survival of patients tested to be resistant in vitro using ATP tumor chemosensitivity assays performed on tumor cells isolated from biopsies.

A more personalized, tumor-specific treatment for EOC patients would be of great value to improve therapeutic decision-making and clinical outcome.

The aim of this Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays.

The aim of this Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays.

The van Altena Research Team concluded in their Oncotarget Research Paper, “our study shows the feasibility of assessing in vitro chemotherapy sensitivity on tumor cells isolated from ascites. A larger, prospective study, which takes into account the insights that were gained in this pilot study, is ongoing and will be reported in due course.“

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27827

Full text – https://www.oncotarget.com/article/27827/text/

Correspondence to – Anne M. van Altena – [email protected]

Keywords –
ovarian cancer,
chemotherapy sensitivity,
prediction,
ascites,
proliferation assays

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
RYAN JAMES JESSUP
[email protected]

Original Source

https://www.oncotarget.com/news/pr/sensitivity-testing-on-ovarian-cancer-cells-isolated-from-malignant-ascites/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27827

Tags: BiologyBreast CancerBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/EthicsProstate Cancer
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling

April 10, 2021
IMAGE

Vaping vs. smoking: Impact on cells compared

April 9, 2021

Artificial Intelligence could ‘crack the language of cancer and Alzheimer’s’

April 8, 2021

Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma

April 8, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    851 shares
    Share 340 Tweet 213
  • Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    59 shares
    Share 24 Tweet 15
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    55 shares
    Share 22 Tweet 14
  • A sturdier spike protein explains the faster spread of coronavirus variants

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsCell BiologyBiologyPublic HealthMedicine/HealthcancerInfectious/Emerging DiseasesMaterialsTechnology/Engineering/Computer ScienceClimate ChangeChemistry/Physics/Materials SciencesEcology/Environment

Recent Posts

  • Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling
  • Level of chromosomal abnormality in lung cancer may predict immunotherapy response
  • Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
  • Better metric for thermoelectric materials means better design strategies
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In